Superintelligence vs. clinical trials: The ultimate boss fight

Plus: Xaira’s antibodies succeed where earlier attempts failed, AI cell models get a fairer test, and Ortet launches with a $500 million commitment.

Peter Ottsjö

Oct 4, 2026

•